Ozempic for weight loss: separating the real results from the hype

What did @el13cl actually say?

Honestly, the transcript we have from this video is nearly useless for a clean fact-check. The auto-generated captions appear corrupted or mistranslated, leaving us with fragments about "weapons" and "Japan" that bear no relationship to what the Chilean morning show segment was actually about. What we do know from the caption: panelist José María del Pino appeared on Tu Día (Canal 13, Chile) to share his personal experience using Ozempic, reaching a weight of 73 kilograms. That framing, a public figure sharing a weight-loss story tied to a diabetes drug, is exactly the kind of content that needs scrutiny.

The narrative structure here is familiar: someone well-known uses a medication originally developed for type 2 diabetes, loses weight, appears on television, and 1.3 million people watch. That reach matters because personal testimonials carry emotional weight that clinical data simply does not, especially when the speaker is likable and the results are visible.

Does the science back up Ozempic for weight loss?

Yes, but with real asterisks. Semaglutide, the active ingredient in Ozempic and Wegovy, has solid trial data behind it. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) showed participants on 2.4mg weekly semaglutide lost an average of 14.9% of body weight over 68 weeks versus 2.4% on placebo. That is not trivial. The drug works by mimicking GLP-1, a gut hormone that slows gastric emptying, reduces appetite, and signals satiety to the brain.

But Ozempic is approved at 0.5-2mg weekly for type 2 diabetes management, not for weight loss specifically. Wegovy, the higher-dose version, carries the weight-loss indication. When people use Ozempic off-label for weight loss, they are operating outside the approved dosing structure, which is worth knowing. Additionally, weight regained rapidly after stopping the drug in trials (Wilding et al., 2022, Diabetes, Obesity and Metabolism), meaning this is a long-term treatment, not a course you finish.

What did they get wrong, or right?

Without a clean transcript, we cannot pin specific errors on the speaker. What we can assess is the category of risk this type of segment carries. Personal testimonials about Ozempic tend to underreport side effects. In the STEP trials, over 70% of participants on semaglutide experienced gastrointestinal side effects including nausea, vomiting, and diarrhea. These are not minor inconveniences for everyone.

There is also a supply problem that television segments rarely mention. Since semaglutide became a lifestyle drug for people without diabetes, actual diabetic patients in multiple countries faced shortages of Ozempic (FDA Drug Shortages database, 2023-2024). A celebrity sharing a feel-good weight-loss story on morning television contributes, however indirectly, to demand that has real consequences for patients who need the drug to manage blood glucose, not body image.

If del Pino was transparent about using it under medical supervision and acknowledged it as a prescription medication requiring ongoing care, that would be the responsible version of this story. If the segment framed it as a simple solution, that is where the harm lives.

What should you actually know about GLP-1 drugs and weight?

Semaglutide is a real drug with real effects and real risks. It is not a supplement, it is not a shortcut you can self-prescribe, and compounded versions circulating outside regulated pharmacies are not equivalent to the brand-name product. Do not let a 90-second TV clip make that decision for you.

• GLP-1 receptor agonists require a prescription and ongoing medical monitoring.
• Not everyone is a candidate. People with a personal or family history of medullary thyroid carcinoma or MEN 2 syndrome should not use semaglutide, per FDA labeling.
• Pancreatitis is a documented risk. The FDA label includes a warning. If you develop severe abdominal pain on this drug, stop and seek care.
• The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) on tirzepatide showed even larger weight reductions, up to 22.5% in some participants, suggesting these drugs will keep evolving.
• Weight management is not a vanity project. These drugs are studied in the context of metabolic disease, cardiovascular risk, and quality of life. The framing matters.

The bottom line on this video

A 1.3 million view testimonial about Ozempic from a public figure is not medical guidance, and it should not function as one. The drug has genuine clinical backing for weight loss, particularly at the Wegovy dosing. But the gap between "it worked for him on TV" and "this is appropriate for you" is where people get hurt. Talk to a licensed provider. Get your metabolic panel. Understand what you are committing to before you start, because the data is clear that stopping has consequences too.